

DIABETES PROGRAM: \_\_\_\_\_

PHONE NUMBER: \_\_\_\_\_

FAX NUMBER: \_\_\_\_\_

Patient Name: \_\_\_\_\_

DOB (dd/mm/yy): \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_

Postal Code: \_\_\_\_\_

Telephone: \_\_\_\_\_

Language Barrier:  YES  NO

Health Card Number: \_\_\_\_\_

Language Spoken: \_\_\_\_\_

**\*\*Discontinue DPP4i's and consider reducing secretagogues/insulin doses when adding a GLP-1 RA or GLP-1/GIP to treatment\*\***

Class	Types/Brands (random order)	Starting/Current Dose	Adjustments
<input type="checkbox"/> GLP-1/GIP injectable	<input type="checkbox"/> Tirzepatide (Mounjaro®) (Available in vial. Multidose Kwikpen available soon)	<input type="checkbox"/> Once weekly, 2.5 mg sc	<input type="checkbox"/> Titrate 2.5 mg every 4 weeks if tolerated and further control is desired, up to _____ mg OR a maximum dose of 15 mg weekly
<input type="checkbox"/> GLP-1 RA injectable	<input type="checkbox"/> Semaglutide (Ozempic®) (pen sizes: 0.5, 1 and 2 mg)	<input type="checkbox"/> Once weekly, 0.25 mg sc	<input type="checkbox"/> Titrate to 0.5 mg in 4 weeks. If tolerated and further control is desired, titrate to 1.0 mg in 4 weeks, up to a maximum dose of 2 mg in another 4 weeks
	<input type="checkbox"/> Liraglutide (Victoza®) <b>(to be phased out March 2026)</b>	<input type="checkbox"/> Daily dosing, 0.6 mg sc	<input type="checkbox"/> Titrate by 0.6 mg every 1-2 weeks if tolerated and further control desired to maximum dose of 1.8 mg
	<input type="checkbox"/> Dulaglutide (Trulicity®) (pen sizes: 0.75, 1.5mg)	<input type="checkbox"/> Once weekly, 0.75 mg sc	<input type="checkbox"/> Titrate in 4 weeks to next dose level, up to maintenance dose of 4.5 mg
<input type="checkbox"/> GLP-1 RA oral	<input type="checkbox"/> Semaglutide (Rybelsus®) (tablet dose: 3, 7, 14 mg)	<input type="checkbox"/> Daily dosing, 3 mg po  Take on empty stomach with no more than ½ cup of water, 30 mins prior to eating/drinking or taking other medications	<input type="checkbox"/> Titrate in 30 days to 7 mg, and further titrate after 30 more days to maximum dose of 14 mg daily if further control is desired
<input type="checkbox"/> Combination GLP-1 agonist + basal insulin	<input type="checkbox"/> Liraglutide + insulin Degludec (Xultophy®) (1 unit contains: 1 unit of Degludec and 0.036mg of Liraglutide) <b>To be phased out Dec 2025</b>	<input type="checkbox"/> Daily injection, start 10 units if insulin naïve, 16 units if currently on basal insulin	<input type="checkbox"/> Adjust dose by 2 units q 3-4 days to achieve optimal FBG. Max dose 50 units (Use another agent if <16 units or >50units)
	<input type="checkbox"/> Lixisenatide + insulin Glargine (Soliqua®) (1 unit contains: 1 unit of Glargine and 0.33ugm of Lixisenatide)	<input type="checkbox"/> Daily injection, 15 units (if already on basal <30 units /day) or 30 units if currently on basal 30-60 units/day)	<input type="checkbox"/> Adjust dose by 2-4 units q weekly to achieve optimal FBG. Max dose 60 units (Use another agent if >60 units are required)
<input type="checkbox"/> Discontinue the following medications:			
<input type="checkbox"/> Additional notes:			

- Authorize Certified Diabetes Educator to reduce the secretagogue dosage accordingly to avoid hypoglycemia
- Authorize Certified Diabetes Educator to adjust carb/insulin ratios for self management of insulin therapy
- Authorize Certified Diabetes Educator to dispense medication samples for teaching and financial need
- Authorize RD to take blood samples by skin pricking for teaching/ monitoring capillary BG
- Authorize Certified Diabetes Educator to order blood glucose or A1c for assessment and evaluation of glycemic control

**AUTHORIZING PHYSICIAN INFORMATION**

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Print Name: \_\_\_\_\_

Ph#: \_\_\_\_\_

Address (or stamp): \_\_\_\_\_

Fax#: \_\_\_\_\_